跳转至内容
Merck
CN

S7049

D-鞘氨醇

synthetic

别名:

4-鞘氨醇, 反式-D--2-氨基-4-十八烯-1,3-二醇, (2S,3R,4E)-2-氨基-4-十八烯-1,3-二醇

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C18H37NO2
化学文摘社编号:
分子量:
299.49
UNSPSC Code:
12352211
NACRES:
NA.77
PubChem Substance ID:
EC Number:
204-651-3
Beilstein/REAXYS Number:
1727294
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

D-鞘氨醇, synthetic

InChI

1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1

InChI key

WWUZIQQURGPMPG-KRWOKUGFSA-N

SMILES string

OC[C@@](N)([H])[C@]([H])(O)/C=C/CCCCCCCCCCCCC

biological source

synthetic

assay

≥98% (TLC)

form

powder

mp

74.2-78.1 °C

solubility

chloroform: complete 20 mg/mL, clear, colorless

lipid type

sphingolipids

storage temp.

−20°C

Quality Level

Gene Information

rat ... Prkca(24680)

正在寻找类似产品? 访问 产品对比指南

Application

已研究了 D-Sphingosine(合成的)对真菌莱氏野村菌的发芽活性的影响。8

Biochem/physiol Actions

细胞膜的一种组成部分。神经酰胺的前体。蛋白激酶 C 的选择性抑制剂,但不抑制蛋白激酶  A 或肌球蛋白轻链激酶。钙调蛋白依赖性酶的抑制剂。
鞘氨醇的天然异构体

hcodes

Hazard Classifications

Aquatic Chronic 4

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S S Reddy et al.
The Journal of clinical investigation, 84(5), 1569-1576 (1989-11-01)
Leprechaunism is a rare genetic disorder characterized by severe growth retardation and insulin resistance. Maximal epidermal growth factor (EGF) binding was reduced in fibroblasts from three unrelated patients with leprechaunism (Ark-1, Can-1, and Minn-1) compared with control (0.8-2.2%/mg protein vs.
Susan M Hancock et al.
Nature chemical biology, 5(7), 508-514 (2009-06-16)
Though glycosphingolipids have great potential as therapeutics for cancer, HIV, neurodegenerative diseases and auto-immune diseases, both extensive study of their biological roles and development as pharmaceuticals are limited by difficulties in their synthesis, especially on large scales. Here we addressed
Meret E Ricklin et al.
Neurology, 81(2), 174-181 (2013-05-24)
To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy. The VZV-specific immune response was studied using interferon (IFN)-γ enzyme-linked immunosorbent spot assay, proliferation assays, and upregulation of T-cell activation markers
Vilija G Jokubaitis et al.
Neurology, 82(14), 1204-1211 (2014-03-13)
To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse
David Henault et al.
Neurology, 81(20), 1768-1772 (2013-10-18)
To determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4- to 7-year period in patients with MS receiving fingolimod (FTY720) and the relation between TLCs and T-cell subsets (CD4+, CD8+, CCR7+/-) that are

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持